Over 400 Genetic Bone Disorders | Pattern Recognition | Radiographic Diagnosis
RADIOGRAPHIC CLASSIFICATION
Critical Must-Knows
- Achondroplasia - FGFR3 mutation, rhizomelic shortening, champagne-glass pelvis, spinal stenosis
- Osteogenesis imperfecta - collagen type I defect, blue sclerae, fractures, bisphosphonate treatment
- Pattern recognition - look at bone density (decreased/increased) and shape (epiphyseal/metaphyseal/diaphyseal)
- Spinal complications - cervical instability, kyphosis, stenosis are major surgical considerations
- New treatments - vosoritide for achondroplasia, bisphosphonates for OI, enzyme replacement for MPS
Clinical Pearls
- "Achondroplasia: FGFR3 mutation, autosomal dominant, normal intelligence, spinal stenosis risk
- "OI Type I: blue sclerae, hearing loss - Type II is lethal
- "Mucopolysaccharidoses show dysostosis multiplex on X-ray
- "Osteopetrosis: dense but brittle bones - osteoclast dysfunction
Clinical Imaging
Imaging Gallery
Critical Skeletal Dysplasia Exam Points
Achondroplasia
FGFR3 mutation causing decreased endochondral ossification. Rhizomelic shortening (proximal limbs), champagne-glass pelvis, frontal bossing, trident hand. Major orthopaedic issues: foramen magnum stenosis, spinal stenosis, genu varum.
Osteogenesis Imperfecta
Collagen type I defect (COL1A1/COL1A2). Blue sclerae, fragile bones, hearing loss. Type I (mild, blue sclerae) to Type II (lethal). Treatment: bisphosphonates, rodding procedures. Beware NAI misdiagnosis.
Mucopolysaccharidoses
Lysosomal storage disorders - enzyme deficiency leads to GAG accumulation. Dysostosis multiplex on X-ray. Hurler (MPS I) most severe, Morquio (MPS IV) has unique skeletal features. Enzyme replacement available for some.
Sclerosing Dysplasias
Osteopetrosis - osteoclast dysfunction causing dense but brittle bones. Erlenmeyer flask deformity, sandwich vertebrae. Severe form needs BMT. Pyknodysostosis - dense bones + acroosteolysis (Toulouse-Lautrec had this).
At a Glance
Skeletal dysplasias encompass 400+ genetic bone disorders (collective incidence ~1:5,000) classified by radiographic pattern: osteopenic (OI), sclerosing (osteopetrosis), short-limbed (achondroplasia), or short-trunk (SED, Morquio). Achondroplasia (most common viable dysplasia, 1:25,000) results from FGFR3 gain-of-function mutation causing rhizomelic shortening, champagne-glass pelvis, trident hand, and progressive spinal stenosis. Osteogenesis imperfecta (COL1A1/COL1A2 collagen type I defects) presents with blue sclerae, fractures, hearing loss, and dentinogenesis imperfecta—treated with bisphosphonates and rodding procedures. Mucopolysaccharidoses (lysosomal storage disorders) show dysostosis multiplex on X-ray (J-shaped sella, hook vertebrae, paddle ribs). Spinal complications (cervical instability, stenosis, kyphosis) are major surgical considerations across dysplasia types. Newer treatments include vosoritide for achondroplasia and enzyme replacement for MPS.
STAMPAchondroplasia Features - STAMP
| S | Spinal stenosis Narrow canal, short pedicles - major long-term issue |
| T | Trident hand Persistent space between 3rd and 4th fingers |
| A | Autosomal dominant, FGFR3 Gain-of-function mutation, 80% new mutations |
| M | Macrocephaly and frontal bossing Large head, prominent forehead, midface hypoplasia |
| P | Pelvis champagne-glass Horizontal acetabular roofs, narrow sacrosciatic notch |
| S | Spinal stenosis Narrow canal, short pedicles - major long-term issue | M | Macrocephaly and frontal bossing Large head, prominent forehead, midface hypoplasia |
| T | Trident hand Persistent space between 3rd and 4th fingers | P | Pelvis champagne-glass Horizontal acetabular roofs, narrow sacrosciatic notch |
| A | Autosomal dominant, FGFR3 Gain-of-function mutation, 80% new mutations |
Hook:STAMP the diagnosis - achondroplasia leaves its STAMP on the skeleton
BONEDOsteogenesis Imperfecta Features - BONED
| B | Blue sclerae Thin sclerae show underlying choroidal vessels |
| O | Osteopenia and fractures Multiple fractures, especially long bones |
| N | Normal intelligence Cognition unaffected, distinguish from NAI |
| E | Ear - hearing loss Conductive then sensorineural (otosclerosis) |
| D | Dentinogenesis imperfecta Opalescent teeth, Type I collagen in dentin |
| B | Blue sclerae Thin sclerae show underlying choroidal vessels | E | Ear - hearing loss Conductive then sensorineural (otosclerosis) |
| O | Osteopenia and fractures Multiple fractures, especially long bones | D | Dentinogenesis imperfecta Opalescent teeth, Type I collagen in dentin |
| N | Normal intelligence Cognition unaffected, distinguish from NAI |
Hook:BONED - brittle bones need this easy mnemonic
JDHIPDysostosis Multiplex Features - JDHIP
| J | J-shaped sella Anterior extension of sella turcica |
| D | Diaphyseal widening Expanded medullary canals in long bones |
| H | Hook vertebrae Anteroinferior beaking of vertebral bodies |
| I | Inferior beaking of L1/L2 Hypoplastic vertebra at thoracolumbar junction |
| P | Paddle ribs Widened, oar-shaped ribs |
| J | J-shaped sella Anterior extension of sella turcica | I | Inferior beaking of L1/L2 Hypoplastic vertebra at thoracolumbar junction |
| D | Diaphyseal widening Expanded medullary canals in long bones | P | Paddle ribs Widened, oar-shaped ribs |
| H | Hook vertebrae Anteroinferior beaking of vertebral bodies |
Hook:JDHIP - J-shaped sella, Dysostosis, Hook vertebrae = MPS storage diseases
Overview and Epidemiology
Skeletal dysplasias are a heterogeneous group of over 400 genetic disorders affecting bone and cartilage development. While individually rare, they collectively represent a significant burden of genetic skeletal disease with an overall incidence of approximately 1 in 5000 live births. [1,2]
Nosology and Classification: The Nosology and Classification of Genetic Skeletal Disorders (revised periodically by the International Skeletal Dysplasia Society) currently recognizes 461 different conditions organized into 42 groups based on clinical, radiographic, and molecular criteria.
Major Categories by Affected Structure:
- Disorders of cartilage growth (achondroplasia group)
- Disorders of collagen synthesis (osteogenesis imperfecta)
- Lysosomal storage disorders (mucopolysaccharidoses)
- Disorders of mineral homeostasis (rickets, hypophosphatasia)
- Disorders of bone resorption (osteopetrosis)
Pattern Recognition
Radiographic diagnosis of skeletal dysplasias primarily relies on pattern recognition. Key features to assess: (1) Bone density - decreased (osteopenic) or increased (sclerosing); (2) Which part of the bone is affected - epiphyseal, metaphyseal, or diaphyseal; (3) Limb proportions - rhizomelic (proximal), mesomelic (middle), or acromelic (distal); (4) Spine involvement - platyspondyly, vertebral beaking.
Common Viable Skeletal Dysplasias:
- Achondroplasia (1:25,000) - most common
- Osteogenesis imperfecta (1:15,000)
- Spondyloepiphyseal dysplasia (1:100,000)
- Multiple epiphyseal dysplasia (1:100,000)
- Cleidocranial dysplasia (1:1,000,000)
Pathophysiology
Molecular Basis
Skeletal dysplasias result from mutations affecting various pathways:
Molecular Pathways in Skeletal Dysplasias
| Pathway/Gene | Dysplasia | Effect |
|---|---|---|
| FGFR3 | Achondroplasia, thanatophoric dysplasia | Gain-of-function inhibits chondrocyte proliferation |
| COL1A1/COL1A2 | Osteogenesis imperfecta | Abnormal type I collagen synthesis |
| COL2A1 | SED congenita, Stickler syndrome | Abnormal type II collagen in cartilage |
| Lysosomal enzymes | Mucopolysaccharidoses | GAG accumulation in tissues |
| TCIRG1/CLCN7 | Osteopetrosis | Osteoclast dysfunction - no resorption |
| RUNX2 | Cleidocranial dysplasia | Defective intramembranous ossification |
Bone Formation Affected
Endochondral Ossification Disorders:
- Achondroplasia group - growth plate dysfunction
- Epiphyseal dysplasias - cartilage model affected
- Most short-limbed dwarfism
Intramembranous Ossification Disorders:
- Cleidocranial dysplasia - clavicle, skull
- Affects flat bones
Combined Disorders:
- Osteogenesis imperfecta - affects all type I collagen-containing tissues
- Osteopetrosis - affects bone remodeling throughout skeleton
Classification
Radiographic Classification Approach
Osteopenic Dysplasias (Decreased Density):
- Osteogenesis imperfecta - fragile bones, multiple fractures
- Hypophosphatasia - rickets-like changes, deficient alkaline phosphatase
- Idiopathic juvenile osteoporosis
Sclerosing Dysplasias (Increased Density):
- Osteopetrosis - diffuse sclerosis, Erlenmeyer flask
- Pyknodysostosis - sclerosis + acroosteolysis
- Osteopoikilosis - spotty sclerosis (benign)
- Melorheostosis - flowing candle wax appearance
Density assessment on radiograph is the first step in classifying an unknown skeletal dysplasia. This immediately narrows the differential diagnosis.
Clinical Presentation
Skeletal dysplasias present with characteristic clinical features that guide initial diagnosis:
General Presentation Patterns
Short Stature:
- Proportionate vs disproportionate (most skeletal dysplasias)
- Short limb vs short trunk patterns
- Measure arm span, sitting height, upper/lower segment ratio
Disproportionate Short Stature Patterns:
- Rhizomelic: Proximal segment shortened (achondroplasia)
- Mesomelic: Middle segment shortened (Langer mesomelic)
- Acromelic: Distal segment shortened (acromicric dysplasia)
- Short trunk: Spine predominantly affected (SED, Morquio)
Specific Clinical Signs
Key Clinical Signs by Dysplasia
| Sign | Dysplasia | Significance |
|---|---|---|
| Blue sclerae | Osteogenesis imperfecta Type I | Thin sclerae showing choroid vessels |
| Frontal bossing | Achondroplasia | Large head with prominent forehead |
| Trident hand | Achondroplasia | Gap between 3rd and 4th fingers |
| Approximate shoulders | Cleidocranial dysplasia | Absent/hypoplastic clavicles |
| Coarse facies | MPS (Hurler, Hunter) | GAG accumulation in soft tissues |
| Corneal clouding | MPS I (Hurler/Scheie) | NOT in Hunter syndrome |
History Taking
Family History:
- Pattern of inheritance (AD, AR, X-linked)
- 80% of achondroplasia cases are new mutations
- Parental age (increased paternal age associated with new dominant mutations)
Developmental History:
- Motor milestones - often delayed in severe forms
- Cognitive development - normal in most (except MPS types I-III)
- Growth velocity and pattern
Associated Symptoms:
- Respiratory issues (thoracic involvement, obstructive sleep apnoea)
- Hearing loss (OI, MPS)
- Visual problems (corneal clouding in MPS)
- Joint pain/stiffness
Differential Diagnosis
Differential Diagnosis of Disproportionate Short Stature
| Condition | Pattern / Body Segment | Discriminating Feature | Confirmatory Test |
|---|---|---|---|
| Achondroplasia | Rhizomelic short-limb | Frontal bossing, trident hand, champagne-glass pelvis | FGFR3 G380R mutation |
| Hypochondroplasia | Mild rhizomelic short-limb | Milder than achondroplasia, often normal facies | FGFR3 (non-G380R) mutation |
| Thanatophoric dysplasia | Severe rhizomelic, lethal | Narrow thorax, telephone-receiver femora | FGFR3 mutation (lethal alleles) |
| Spondyloepiphyseal dysplasia (SED) | Short-trunk | Platyspondyly plus epiphyseal change, odontoid hypoplasia | COL2A1 mutation |
| Morquio (MPS IVA) | Short-trunk | Normal intelligence, dysostosis multiplex, corneal clouding | Urine GAG, GALNS enzyme assay |
| Osteogenesis imperfecta (severe) | Short-limb with deformity | Blue sclerae, fractures, Wormian bones | COL1A1/COL1A2 mutation |
| Pseudoachondroplasia | Rhizomelic short-limb | Normal facies/skull, marked epiphyseal/metaphyseal change | COMP mutation |
| Rickets (nutritional/hypophosphataemic) | Disproportionate, acquired | Metaphyseal fraying/cupping, bowing, low/normal Ca | ALP, phosphate, vitamin D, PHEX |
Investigations
Radiographic Assessment
The skeletal survey is the cornerstone of diagnosis in skeletal dysplasias:
Standard Skeletal Survey:
- Skull (AP, lateral)
- Spine (AP, lateral)
- Chest (AP)
- Pelvis (AP)
- Long bones (humerus, radius/ulna, femur, tibia/fibula)
- Hand (AP)
Systematic Radiographic Evaluation:
-
Bone Density Assessment
- Decreased: OI, hypophosphatasia
- Increased: osteopetrosis, pyknodysostosis
-
Location of Involvement
- Epiphyseal: MED, SED, chondrodysplasia punctata
- Metaphyseal: achondroplasia, rickets, metaphyseal chondrodysplasia
- Diaphyseal: progressive diaphyseal dysplasia, melorheostosis
-
Limb Proportions
- Measure humerus and femur lengths
- Calculate rhizomelic ratio
-
Spine Evaluation
- Vertebral height and shape
- Interpedicular distance
- Platyspondyly, beaking, stenosis
Genetic Testing
Indications:
- Confirm clinical/radiographic diagnosis
- Genetic counselling
- Prenatal diagnosis in subsequent pregnancies
- Access to specific treatments
Methods:
- Single gene testing (when diagnosis clear)
- Skeletal dysplasia gene panels (50-500 genes)
- Exome/genome sequencing (atypical presentations)
Laboratory Tests
Osteogenesis Imperfecta:
- Bone markers, vitamin D, calcium
- Collagen analysis (skin biopsy, historical)
- Genetic testing (COL1A1/COL1A2)
Mucopolysaccharidoses:
- Urine GAG screening (dermatan sulfate, heparan sulfate)
- Enzyme assay in leukocytes (specific enzyme for each MPS type)
- Genetic confirmation
Metabolic Bone Disease:
- Alkaline phosphatase (low in hypophosphatasia)
- Calcium, phosphate, vitamin D
- PTH levels
Additional Imaging
MRI:
- Foramen magnum stenosis assessment (achondroplasia)
- Spinal stenosis evaluation
- Cervical cord compression
- Brain MRI if developmental concerns
CT:
- 3D reconstruction for surgical planning
- Cervical spine assessment
Echocardiography:
- Cardiac involvement in MPS
- Aortic root in Marfan syndrome (connective tissue, not dysplasia)
Achondroplasia
Achondroplasia is the most common viable skeletal dysplasia, caused by gain-of-function mutations in the FGFR3 gene. [3,4]
Genetics and Pathophysiology
- Gene: FGFR3 (fibroblast growth factor receptor 3) on chromosome 4p16.3
- Mutation: G380R (glycine to arginine) in 97% of cases
- Inheritance: Autosomal dominant, but 80% are new mutations
- Mechanism: Constitutive activation of FGFR3 inhibits chondrocyte proliferation in growth plates
FGFR3 Mutation Spectrum
FGFR3 mutations cause a spectrum of severity: Thanatophoric dysplasia (most severe, lethal) through SADDAN syndrome to Achondroplasia to Hypochondroplasia (mildest). All are gain-of-function mutations with varying degrees of receptor activation.
Clinical Features
Craniofacial:
- Macrocephaly with frontal bossing
- Midface hypoplasia
- Depressed nasal bridge
- Normal intelligence
Skeletal:
- Rhizomelic shortening (proximal limbs most affected)
- Trident hand configuration
- Genu varum (tibial bowing)
- Thoracolumbar kyphosis (in infancy)
- Exaggerated lumbar lordosis (develops later)
Radiographic Features
Radiographic Features of Achondroplasia
| Region | Finding | Clinical Significance |
|---|---|---|
| Skull | Enlarged calvarium, small skull base, foramen magnum stenosis | Risk of cervicomedullary compression |
| Spine | Narrow interpedicular distance caudally, short pedicles, small canal | Spinal stenosis - major cause of morbidity |
| Pelvis | Champagne-glass shape, horizontal acetabular roofs, narrow sciatic notch | Characteristic diagnostic feature |
| Long bones | Rhizomelic shortening, metaphyseal flaring, chevron deformity of femur | Affects endochondral ossification |
| Hand | Trident configuration, short tubular bones | Persistent gap between 3rd and 4th fingers |
Orthopaedic Management
Spinal Issues:
- Foramen magnum stenosis - monitor in infancy, decompression if symptomatic
- Thoracolumbar kyphosis - bracing, fusion if progressive
- Spinal stenosis - develops in adults, may need multilevel decompression
Lower Limb:
- Genu varum - guided growth or osteotomy
- Limb lengthening - controversial, significant complications
- Avoid obesity to reduce mechanical stress
New Treatments:
- Vosoritide (C-natriuretic peptide analogue) - FDA approved 2021
- Works by antagonizing FGFR3 signaling
- Shown to increase growth velocity in clinical trials
Osteogenesis Imperfecta
Osteogenesis imperfecta (OI) is a group of genetic disorders affecting type I collagen, resulting in bone fragility and other connective tissue manifestations. [5,6]
Genetics
- Genes: Primarily COL1A1 and COL1A2 (encode type I collagen)
- Inheritance: Mostly autosomal dominant (Types I-IV)
- Newer genes: CRTAP, LEPRE1, PPIB (recessive forms)
Sillence Classification
Sillence Classification of Osteogenesis Imperfecta
| Type | Severity | Sclerae | Key Features |
|---|---|---|---|
| Type I | Mild | Blue | Fractures after walking, normal stature, hearing loss common |
| Type II | Lethal | Dark blue | Multiple intrauterine fractures, beaded ribs, perinatal death |
| Type III | Severe | Variable | Progressive deformity, short stature, wheelchair by teens |
| Type IV | Moderate | White/blue | Moderate fragility, normal sclerae in adults, dentinogenesis imperfecta |
Clinical Features
Classic Triad:
- Blue sclerae (thin sclerae showing choroidal vessels)
- Bone fragility (multiple fractures)
- Hearing loss (conductive then sensorineural)
Other Features:
- Dentinogenesis imperfecta (opalescent teeth)
- Joint hypermobility
- Easy bruising
- Short stature (severe forms)
- Basilar invagination (Type III)
NAI Misdiagnosis
OI can be mistaken for non-accidental injury (NAI) due to multiple unexplained fractures. Key differentiators: blue sclerae, family history, Wormian bones on skull X-ray, osteopenia, and genetic testing. Always consider OI before diagnosing NAI in an infant with fractures.
Radiographic Features
- Generalized osteopenia
- Multiple fractures at various stages of healing
- Wormian bones (multiple small bones in skull sutures)
- Codfish vertebrae (biconcave)
- Gracile long bones
- Popcorn calcification in epiphyses (severe forms)
Management
Medical:
- Bisphosphonates (pamidronate, zoledronic acid) - increase BMD, reduce fractures
- Calcium and vitamin D supplementation
- Physical therapy - strengthen muscles, prevent falls
Surgical:
- Intramedullary rodding - stabilize long bones, prevent deformity
- Telescoping rods (Bailey-Dubow, Fassier-Duval) - grow with child
- Spinal fusion for scoliosis
- Basilar impression decompression if needed
Rodding Principles
Intramedullary rodding in OI uses telescoping designs that elongate with growth. Key principles: rod both femurs and tibias for walking patients, use solid rods for non-ambulatory patients, fixation should span entire bone, and augment with bisphosphonates pre- and post-operatively.
Mucopolysaccharidoses
The mucopolysaccharidoses (MPS) are lysosomal storage disorders caused by deficiency of enzymes that degrade glycosaminoglycans (GAGs). The accumulation of GAGs in tissues causes progressive multisystem disease. [7]
Classification
Mucopolysaccharidoses Types
| Type | Name | Enzyme Deficiency | Key Features |
|---|---|---|---|
| MPS I | Hurler/Scheie | Alpha-L-iduronidase | Most severe, cognitive decline, corneal clouding |
| MPS II | Hunter | Iduronate sulfatase | X-linked, no corneal clouding, variable severity |
| MPS III | Sanfilippo | Various heparan sulfate enzymes | Behavioral issues, mild skeletal involvement |
| MPS IV | Morquio | Galactose-6-sulfatase (A) or B-galactosidase (B) | Normal intelligence, severe skeletal involvement, odontoid hypoplasia |
| MPS VI | Maroteaux-Lamy | Arylsulfatase B | Normal intelligence, severe skeletal involvement |
Dysostosis Multiplex
The radiographic constellation of findings in MPS is termed "dysostosis multiplex":
- J-shaped sella turcica
- Paddle-shaped (oar-shaped) ribs
- Hook-shaped vertebrae with anteroinferior beaking
- Diaphyseal widening of long bones
- Bullet-shaped metacarpals with proximal pointing
- Hypoplastic L1/L2 vertebra causing kyphosis
Orthopaedic Considerations
Cervical Spine:
- Odontoid hypoplasia (especially Morquio)
- Atlantoaxial instability
- Cervical stenosis
- May need occipitocervical fusion
Thoracolumbar Spine:
- Gibbus deformity at thoracolumbar junction
- Progressive kyphosis
- May need spinal fusion
Lower Limb:
- Genu valgum (especially Morquio)
- Hip dysplasia
- Guided growth or osteotomy
Treatment
Medical:
- Enzyme replacement therapy (ERT) - available for MPS I, II, IVA, VI
- Hematopoietic stem cell transplant - best if early, for MPS I
- Gene therapy - under investigation
Surgical:
- Address spinal instability early
- Joint procedures as needed
- Cardiac valve surgery in some types
Morquio Syndrome
Morquio syndrome (MPS IVA) has unique features: normal intelligence, severe skeletal involvement, odontoid hypoplasia with atlantoaxial instability. These patients need cervical spine precautions for any anaesthesia. Always obtain flexion-extension cervical spine imaging before surgery.
Other Important Dysplasias
Osteopetrosis ("Marble Bone Disease"):
- Osteoclast dysfunction - failure of bone resorption
- Diffuse sclerosis but paradoxically brittle bones
- Erlenmeyer flask deformity (failure of metaphyseal remodeling)
- Sandwich vertebrae, bone-within-bone appearance
- Severe form: pancytopenia, cranial nerve compression
- Treatment: BMT for severe infantile form
Pyknodysostosis:
- Cathepsin K deficiency
- Dense bones + acroosteolysis (terminal phalangeal resorption)
- Open fontanelles, micrognathia
- Toulouse-Lautrec reportedly had this condition
- Fractures common despite dense appearance
Sclerosing dysplasias paradoxically have fragile bones despite increased radiographic density due to abnormal bone remodeling.
Management
Management of skeletal dysplasias requires a multidisciplinary approach addressing both medical and orthopaedic needs.
Targeted Drug Therapies:
- Vosoritide (achondroplasia) - C-natriuretic peptide analogue, FDA approved 2021
- Bisphosphonates (OI) - pamidronate, zoledronic acid to increase BMD
- Enzyme replacement (MPS) - laronidase (MPS I), idursulfase (MPS II), elosulfase (MPS IVA)
- HSCT (MPS I severe) - best outcomes if performed early
Supportive Medical Care:
- Growth hormone - not effective in most true skeletal dysplasias
- Vitamin D and calcium supplementation
- Respiratory support - CPAP for obstructive sleep apnoea
- Pain management - multimodal approach
Monitoring:
- Regular growth measurements
- Sleep studies for at-risk patients
- Cardiac echo for MPS patients
- Hearing and vision screening
The medical management aims to optimize quality of life and address systemic manifestations.
Surgical Technique
Intramedullary Rodding in OI
Indications:
- Recurrent fractures (greater than 2 per year in same bone)
- Progressive bowing deformity
- Anticipated fracture through osteopenic segment
- Femur and tibia most commonly rodded
Principles:
- Correct angular deformity with osteotomies if needed
- Rod should span entire bone length
- Avoid stress risers at rod ends
- Combine with bisphosphonate therapy
Rod Types:
| Rod Type | Mechanism | Best For | Consideration |
|---|---|---|---|
| Solid rod (Rush, Steinmann) | Fixed length | Non-ambulatory patients | Needs replacement with growth |
| Bailey-Dubow | Telescopes at metaphysis | Growing children | Complex, can malfunction |
| Fassier-Duval | Telescopes at diaphysis | Growing children | Newer design, better function |
Deformity Correction Osteotomies
Technique:
- Multiple osteotomies through apex of deformity
- "Shish-kebab" technique - threading fragments on rod
- Minimal periosteal stripping to preserve blood supply
Complications
Orthopaedic Complications
Spinal Complications:
- Foramen magnum stenosis (achondroplasia) - brainstem compression
- Spinal stenosis - progressive neurological deficit
- Atlantoaxial instability (MPS, SED) - risk of cord injury
- Cervical kyphosis (diastrophic dysplasia) - may need early fusion
- Basilar invagination (OI) - cranial settling
- Progressive scoliosis - respiratory compromise
Lower Limb Complications:
- Angular deformity progression - genu varum/valgum
- Premature osteoarthritis (MED, SED)
- Pathological fractures (OI, osteopetrosis paradoxically)
- Hip dysplasia and dislocation (MPS, congenital dysplasias)
- Growth plate injury from recurrent fractures
Joint Complications:
- Early-onset degenerative disease
- Joint contractures (MPS)
- Ligamentous laxity (OI, Ehlers-Danlos overlap)
Medical Complications
Medical Complications by Dysplasia Type
| Condition | Complication | Management |
|---|---|---|
| Achondroplasia | Obstructive sleep apnoea, obesity | Sleep study, CPAP, weight management |
| OI | Hearing loss, respiratory failure (severe) | Audiology, pulmonology input |
| MPS | Cardiac valve disease, cognitive decline | Echo surveillance, HSCT if eligible |
| Osteopetrosis (severe) | Pancytopenia, blindness, deafness | BMT, supportive care |
| Thanatophoric dysplasia | Respiratory failure (lethal) | Perinatal palliative care |
Surgical Complications
Fracture Fixation in Abnormal Bone:
- OI: Implant cutout, refracture at implant ends
- Osteopetrosis: Difficult drilling, delayed healing
- Solution: Telescoping rods in OI, staged treatment
Spinal Surgery:
- Dural ectasia (some syndromes)
- Abnormal anatomy
- Difficult intubation (short neck, atlantoaxial instability)
- Increased bleeding risk
Anaesthetic Considerations
Cervical spine instability: Morquio, SED, Down syndrome - fibreoptic intubation may be needed. Difficult airway: short neck, large tongue, restricted mouth opening (MPS). Always have experienced anaesthesia team for skeletal dysplasia patients.
Postoperative Care
General Postoperative Principles
Immediate Postoperative:
- Close neurological monitoring after spinal procedures
- Pain management - multimodal approach
- Early mobilization when safe
- DVT prophylaxis (mechanical, consider chemical in adults)
Fracture/Rodding Postoperative:
- Protected weight bearing initially
- Serial radiographs to confirm healing
- Monitor for implant complications
- Resume bisphosphonates when appropriate
Rehabilitation
| Procedure | Mobilization | Weight Bearing | Return to Activity |
|---|---|---|---|
| IM rodding femur | Day 1-2 | PWB 6 weeks, WBAT 12 weeks | 4-6 months |
| IM rodding tibia | Day 1-2 | PWB 6 weeks, WBAT 12 weeks | 4-6 months |
| Cervical fusion | Collar 6-12 weeks | N/A | 3-6 months |
| Spinal decompression | Day 1 | Full | 6-12 weeks |
Outcomes
Outcomes by Condition
Achondroplasia:
- Life expectancy near normal with appropriate management
- Foramen magnum decompression highly effective when needed
- Spinal stenosis surgery improves quality of life
- Vosoritide showing promise for improved height outcomes
Osteogenesis Imperfecta:
- Bisphosphonates: 30-50% reduction in fracture rate
- Rodding: 90%+ reduction in fractures in rodded bones
- Quality of life significantly improved with modern management
- Type II remains uniformly lethal
Surgical Outcomes Summary
| Procedure | Success Rate | Complications | Revision Rate |
|---|---|---|---|
| IM rodding (OI) | 85-95% | Rod migration, refracture | 20-30% (growth) |
| Foramen magnum decompression | 90%+ | CSF leak, infection | 5-10% |
| Cervical fusion (MPS) | 80-90% | Nonunion, progression | 10-15% |
| Spinal stenosis decompression | 70-80% | Instability, recurrence | 15-20% |
Evidence Base
- First disease-modifying therapy for achondroplasia (C-natriuretic peptide analogue)
- 1.57 cm/year increase in annualised growth velocity over placebo
- Final adult-height impact and long-term harms remain unknown
- Bisphosphonates increase BMD in children and adults with OI
- Fracture-reduction evidence is inconsistent and not conclusive
- Optimal agent, dose, duration and long-term safety remain undefined
- ERT improves respiratory function and physical capacity in MPS I
- No reversal of established skeletal (dysostosis multiplex) changes
- Supports early treatment before irreversible bony deformity
- Collective birth prevalence of skeletal dysplasias ~3 per 10,000
- OI and the FGFR3 chondrodysplasia group are the largest diagnostic categories
- Lethal forms cluster in stillbirths and terminations, biasing live-birth figures
- Original delineation of OI Types I-IV (Sillence classification)
- Type I: autosomal dominant, blue sclerae, presenile hearing loss
- Perinatal-lethal group (Type II) with crumpled femora and beaded ribs
- 461 recognised skeletal dysplasias in 42 clinical/molecular groups
- A causal gene is now known for 92% of entities
- Reference framework for diagnosis and research in skeletal dysplasia
Clinical Decision Scenarios
Use these scenarios to practise clinical reasoning and management decisions
"Classic presentation of achondroplasia or related FGFR3 disorder. The examiner wants systematic evaluation."
"Important scenario - need to distinguish OI from NAI while ensuring child safety."
"Tests knowledge of MPS complications and perioperative considerations."
"Tests systematic approach to pattern recognition in skeletal dysplasias."
"Tests knowledge of evidence-based management in skeletal dysplasia."
MCQ Practice Points
Clinical Pearl
Q: What is the most common skeletal dysplasia and its genetic basis? A: Achondroplasia, caused by gain-of-function mutation in FGFR3 (fibroblast growth factor receptor 3). This mutation inhibits chondrocyte proliferation in the growth plate, causing rhizomelic (proximal) limb shortening with normal trunk length.
Clinical Pearl
Q: What is the life-threatening complication of achondroplasia in infancy? A: Foramen magnum stenosis causing cervicomedullary compression. The small foramen magnum combined with atlantoaxial instability can cause brainstem compression, central apnea, and sudden death. MRI screening is recommended in the first 2 years.
Clinical Pearl
Q: How do you distinguish spondyloepiphyseal dysplasia (SED) from multiple epiphyseal dysplasia (MED)? A: SED has short trunk with vertebral involvement (platyspondyly) plus epiphyseal abnormalities. MED has normal trunk height with only epiphyseal involvement. Both cause premature osteoarthritis, but SED patients are shorter and have spinal deformity.
Clinical Pearl
Q: What orthopaedic complications are common in achondroplasia? A: Spinal stenosis (lumbar, may need multilevel decompression), foramen magnum stenosis (cervical), thoracolumbar kyphosis (often self-corrects), genu varum (tibial bowing), and atlantoaxial instability. Hip and knee arthroplasty may be challenging due to anatomic variants.
Guidelines, Registries & Global Practice
Global Epidemiology
Skeletal dysplasias are individually rare but collectively important. Population-based data from the Utah Birth Defect Network give a birth prevalence of about 3.0 per 10,000 births (rising to 20 per 10,000 stillbirths), with osteogenesis imperfecta (0.79/10,000), thanatophoric dysplasia (0.43/10,000) and achondroplasia (0.35/10,000) the commonest categories. According to PubMed, see Stevenson DA et al. Am J Med Genet A 2012 (DOI). The International Skeletal Dysplasia Society 2019 Nosology recognises 461 disorders in 42 groups, with a causal gene now identified for 92% — Mortier GR et al. Am J Med Genet A 2019 (DOI). Achondroplasia (the commonest non-lethal dysplasia, roughly 1:25,000-1:30,000) and OI (roughly 1:15,000-1:20,000) account for the bulk of the orthopaedic caseload worldwide; incidence is broadly uniform across populations because most cases of achondroplasia arise from recurrent de novo FGFR3 G380R mutations linked to advanced paternal age.
Guidance Across Jurisdictions
International Guidance and Consensus Statements
| Body / Region | Scope | Key Position |
|---|---|---|
| International Skeletal Dysplasia Society (global) | Nosology & diagnosis | 461-disorder nosology; radiographic group then targeted molecular testing |
| International achondroplasia consensus (Europe/US/Australia) | Achondroplasia lifetime care | Structured foramen-magnum surveillance in infancy; multidisciplinary follow-up |
| NICE / NHS England (UK) | Vosoritide & ERT commissioning | Highly specialised commissioning with defined eligibility and stopping rules |
| FDA (US) / EMA (Europe) / TGA (Australia) | Drug approval | Vosoritide approved (FDA 2021, EMA 2021, TGA 2022); ERT approved for MPS I/II/IVA/VI |
| MPS management consensus (White KK et al.) | Orthopaedic surgery in MPS | Early cervical assessment; flexion-extension imaging before any anaesthesia |
Registry & Disease-Specific Networks
- CLARITY / international OI registries and the Brittle Bone Disease Consortium collect longitudinal fracture, bisphosphonate and rodding outcome data.
- Achondroplasia natural-history and post-marketing registries (e.g. the lifeline / industry-sponsored vosoritide cohorts) track growth, foramen magnum events and spinal stenosis.
- MPS patient registries (Hunter Outcome Survey, MPS I Registry) inform ERT eligibility, cardiac and skeletal surveillance, and long-term safety.
Practice Variation & Access
Global Practice Variation
- Limb lengthening is performed selectively and is more common in parts of Europe and the Middle East than in the UK/Australasia, where it remains controversial.
- Vosoritide funding varies widely: reimbursed in several European systems and through specialised commissioning in the UK, but access elsewhere is often via managed-access or patient programmes.
- HSCT vs ERT sequencing for severe MPS I differs by centre and timing of diagnosis (newborn screening availability).
Australian Access (Local Context)
- Bisphosphonates (OI): pamidronate and zoledronic acid are PBS-listed (authority required, specialist-initiated).
- ERT (MPS): laronidase, idursulfase and elosulfase alfa funded via the Life Saving Drugs Program with strict eligibility/monitoring.
- Vosoritide: TGA approved (2022); access historically through patient-access programmes.
- Referral centres: Royal Children's Hospital Melbourne, Children's Hospital Westmead, Queensland Children's Hospital, Perth Children's Hospital, with structured transition to adult metabolic bone services.
Exam Relevance
Across FRACS, FRCS (Tr & Orth) and international fellowship exams you must recognise common skeletal dysplasias radiographically, understand the orthopaedic complications of achondroplasia and OI, know the principles of telescoping-rod fixation in OI, and recognise cervical instability risks in MPS/SED. Classification by bone density and location is a common viva framework.
SKELETAL DYSPLASIAS
Clinical summary
CLASSIFICATION APPROACH
- •Bone DENSITY first: osteopenic vs sclerosing
- •LOCATION: epiphyseal, metaphyseal, or diaphyseal
- •LIMB proportions: rhizomelic, mesomelic, acromelic
- •SPINE: platyspondyly, beaking, canal size
ACHONDROPLASIA - STAMP
- •S = Spinal stenosis (narrow canal, short pedicles)
- •T = Trident hand (gap between 3rd and 4th fingers)
- •A = Autosomal dominant, FGFR3 gain-of-function
- •M = Macrocephaly, frontal bossing, midface hypoplasia
- •P = Pelvis champagne-glass shaped
OSTEOGENESIS IMPERFECTA - BONED
- •B = Blue sclerae (Type I)
- •O = Osteopenia, multiple fractures
- •N = Normal intelligence (distinguish from NAI)
- •E = Ear - hearing loss (otosclerosis)
- •D = Dentinogenesis imperfecta
OI TYPES
- •Type I = Mild, blue sclerae, hearing loss - MOST COMMON
- •Type II = Lethal, multiple intrauterine fractures
- •Type III = Severe, progressive deformity, wheelchair
- •Type IV = Moderate, white/normal sclerae in adults
DYSOSTOSIS MULTIPLEX (MPS)
- •J-shaped sella turcica
- •Paddle-shaped (oar) ribs
- •Hook vertebrae with anteroinferior beaking
- •Diaphyseal widening of long bones
- •Bullet metacarpals with proximal pointing
MORQUIO SYNDROME (MPS IVA)
- •NORMAL INTELLIGENCE - key differentiator
- •Severe skeletal involvement
- •Odontoid hypoplasia - cervical instability
- •MUST get flex-ext C-spine before any anaesthesia
- •ERT available (elosulfase alfa)
TREATMENT
- •Achondroplasia: vosoritide (C-natriuretic peptide analogue) - FDA 2021
- •OI: bisphosphonates (increase BMD), rodding procedures
- •MPS: ERT for Types I, II, IVA, VI; BMT for Type I
- •Spinal surgery for instability/stenosis
- •Limb surgery for deformity correction
Suggested Reading
- Mortier GR, Cohn DH, Cormier-Daire V, et al. Nosology and classification of genetic skeletal disorders: 2019 revision. Am J Med Genet A. 2019;179(12):2393-2419. doi:10.1002/ajmg.a.61366
- Krakow D, Rimoin DL. The skeletal dysplasias. Genet Med. 2010;12(6):327-341. doi:10.1097/GIM.0b013e3181daae9b
- Horton WA, Hall JG, Hecht JT. Achondroplasia. Lancet. 2007;370(9582):162-172. doi:10.1016/S0140-6736(07)61090-3
- Savarirayan R, Tofts L, Irving M, et al. Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial. Lancet. 2020;396(10252):684-692. doi:10.1016/S0140-6736(20)31541-5
- Marini JC, Forlino A, Bachinger HP, et al. Osteogenesis imperfecta. Nat Rev Dis Primers. 2017;3:17052. doi:10.1038/nrdp.2017.52
- Dwan K, Phillipi CA, Steiner RD, Basel D, Cochrane Cystic Fibrosis and Genetic Disorders Group. Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev. 2016;10:CD005088. doi:10.1002/14651858.CD005088.pub4
- Muenzer J. Overview of the mucopolysaccharidoses. Rheumatology (Oxford). 2011;50 Suppl 5:v4-12. doi:10.1093/rheumatology/ker394
- Rajeshwar N, Behr S, Engel N. A primer on skeletal dysplasias. Emerg Radiol. 2022;29(2):385-408. doi:10.1007/s10140-021-02006-4
- Cheung MS, Glorieux FH. Osteogenesis imperfecta: update on presentation and management. Rev Endocr Metab Disord. 2008;9(2):153-160. doi:10.1007/s11154-008-9074-4
- White KK, Bober MB, Engel N, et al. Practical approach to the orthopedic surgical management of the mucopolysaccharidoses. Mol Genet Metab. 2017;122S:142-149. doi:10.1016/j.ymgme.2017.09.006
- Ireland PJ, Pacey V, Zankl A, et al. Optimal management of complications associated with achondroplasia. Appl Clin Genet. 2014;7:117-125. doi:10.2147/TACG.S51485
- Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet. 1979;16(2):101-116. doi:10.1136/jmg.16.2.101
- Wraith JE, Clarke LA, Beck M, et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). J Pediatr. 2004;144(5):581-588. doi:10.1016/j.jpeds.2004.01.046
- Panda A, Gamanagatti S, Jana M, Gupta AK. Skeletal dysplasias: A radiographic approach and review of common non-lethal skeletal dysplasias. World J Radiol. 2014;6(10):808-825. doi:10.4329/wjr.v6.i10.808
- Shapiro JR, Germain-Lee EL. Osteogenesis imperfecta: effecting the transition from adolescent to adult medical care. J Musculoskelet Neuronal Interact. 2012;12(1):24-27.
Key Guidelines
- International Skeletal Dysplasia Society Nosology 2019
- AAOS/SRS Guidelines on Spinal Management in Skeletal Dysplasias
Additional Reading
- Spranger JW, Brill PW, Superti-Furga A, et al. Bone Dysplasias: An Atlas of Genetic Disorders of Skeletal Development. 4th ed. Oxford University Press; 2018.
- Bonafe L, Cormier-Daire V, Hall C, et al. Nosology and classification of genetic skeletal disorders: 2015 revision. Am J Med Genet A. 2015;167A(12):2869-2892.